Activators of PDE8 and PDE11 would have potential value in the treatment of tumors with hemizygous loss or inactivation of PDE8B of PDE11A, respectively, and potentially in other cAMP-pathway cancers characterized by elevated levels of cAMP. The gene discussed is PDE8B; the disease is cancer.